Stay updated on Pembrolizumab as AML Post-Remission Treatment Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.

Latest updates to the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedThe page shows a revision update from v3.5.2 to v3.5.3, representing a new build of the site. This update does not alter the study details or any information presented to users.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRevision: v3.5.2 is now shown, replacing Revision: v3.5.0. This indicates a site update rather than changes to the study data.SummaryDifference0.1%

- Check57 days agoChange DetectedRevision tag updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2 from the page metadata.SummaryDifference0.1%

- Check85 days agoChange DetectedThe new screenshot shows minor layout and styling updates (e.g., spacing and header tweaks). There are no changes to core study data such as eligibility criteria, outcomes, enrollment, or results.SummaryDifference0.1%

- Check92 days agoChange DetectedSite updated to version v3.4.2. The prior government funding notice was removed; there are no changes to the trial details or page data.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab as AML Post-Remission Treatment Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.